BioCryst to Present at Upcoming Investor Conferences

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq:BCRX) will present at two virtual healthcare conferences: the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET, and the JMP Securities Life Sciences Conference on June 17, 2021, at 1:30 p.m. ET. Investors can access live audio webcasts and replays via the Investors section on BioCryst's website. The company focuses on developing oral medications for rare diseases, including ORLADEYO™ for HAE attack prevention and other investigational therapies.

RESEARCH TRIANGLE PARK, N.C., May 26, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:30 p.m. ET and the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:30 p.m. ET. Both are being conducted as virtual conferences.

Links to a live audio webcast and replay of these presentations may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States, European Union, Japan and the United Kingdom for the prevention of HAE attacks in adults and pediatric patients 12 years and older. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the company’s website at www.biocryst.com.

BCRXW

Investors:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When will BioCryst Pharmaceuticals present at the Jefferies Virtual Healthcare Conference?

BioCryst Pharmaceuticals will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. ET.

What is the date of BioCryst's presentation at the JMP Securities Life Sciences Conference?

BioCryst Pharmaceuticals will present at the JMP Securities Life Sciences Conference on June 17, 2021, at 1:30 p.m. ET.

How can I access BioCryst's conference presentations?

You can access live audio webcasts and replays of BioCryst's presentations via the Investors section on their website.

What is ORLADEYO™ and its significance for BioCryst Pharmaceuticals?

ORLADEYO™ (berotralstat) is an oral medication approved for preventing HAE attacks in patients aged 12 and older, showcasing BioCryst's commitment to treating rare diseases.

What other programs is BioCryst Pharmaceuticals currently developing?

BioCryst is developing several programs including BCX9930, BCX9250, and galidesivir, aimed at treating various rare diseases and conditions.